• Matchmaker businesses

    Multisided platforms can create huge value for society and fortunes for entrepreneurs, says Ian Mann.

  • Future imperfect

    A lack of compassion with ordinary people is crucial to SA’s failures, says Mandi Smallhorne.

  • Will Gordhan be fired?

    An economist ponders the top question concerning those who control international capital flows.

All data is delayed
See More

Adcock profits slump on drug loss

Nov 27 2012 08:12


Company Data


Last traded 308
Change 2
% Change 1
Cumulative volume 1998526
Market cap 0

Last Updated: 25-10-2016 at 05:05. Prices are delayed by 15 minutes. Source: McGregor BFA


Last traded 47
Change 0
% Change 0
Cumulative volume 75681
Market cap 0

Last Updated: 25-10-2016 at 05:00. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Adcock buys Indian medicine business

Drug firms win R2.5bn tender

Aspen buys GSK Aussie drugs for R2.2bn

Cipla to bid for control of SA affiliate

Cipla mum on why it suspended CEO

Aspen boosts profit, Asian unit robust

Johannesburg - South Africa's No 2 drug maker, Adcock Ingram [JSE:AIP], reported a worse-than-expected 9% fall in full-year earnings, hit by the loss of high-margin drugs and unfavourable currency swings.

Adcock said diluted headline earnings per share totalled 422 cents in the year to end-September, from 465c a year earlier.

The results fell short of the 430c forecast by StarMine's SmartEstimate, which gives more weight to forecasts from top rated analysts.

Headline EPS, the main profit gauge in South Africa, excludes certain one-time items.

The company said sales were largely flat at R4.6bn, but it raised its final dividend by 8% to 115c per share.

Adcock has been struggling in recent months after losing three drugs that contributed as much as R200m in sales due to safety reasons while the weaker rand and lower consumer demand added to the headwinds.

Shares in Adcock are down nearly 12% so far this year, far behind its closest rival Aspen Pharmacare [JSE:APN], which has surged more than 60%. 

Follow Fin24 on Twitter, Facebook, Google+ and Pinterest.

adcock ingram  |  earnings reports


Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Company Snapshot

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...

Voting Booth

Do you use all your downloaded apps on your smartphone?

Previous results · Suggest a vote